Finally, in the syngeneic MC38 colorectal model, Imprime not only showed superior reduction of tumor growth when combined with an anti-PD-1 Ab but immune correlative assessment demonstrated that TAMs isolated from Imprime + anti-PD-1 combination-treated tumors were also consistently less suppressive towards CD8, enabling them to take on a more effector phenotype (IFN-γ+IL-2+TNF-α+) when presented with MC38-specific antigens. This evidence concerns the gene TNF and neoplasm.